Literature DB >> 28640659

PHLDA1 (pleckstrin homology-like domain, family A, member 1) knockdown promotes migration and invasion of MCF10A breast epithelial cells.

Naieli Bonatto1,2, Maria José Carlini1,2, Simone Aparecida de Bessa Garcia1,2, Maria Aparecida Nagai1,2.   

Abstract

PHLDA1 (pleckstrin homology-like domain, family A, member 1) is a multifunctional protein that plays distinct roles in several biological processes including cell death and therefore its altered expression has been identified in different types of cancer. Progressively loss of PHLDA1 was found in primary and metastatic melanoma while its overexpression was reported in intestinal and pancreatic tumors. Previous work from our group showed that negative expression of PHLDA1 protein was a strong predictor of poor prognosis for breast cancer disease. However, the function of PHLDA1 in mammary epithelial cells and the tumorigenic process of the breast is unclear. To dissect PHLDA1 role in human breast epithelial cells, we generated a clone of MCF10A cells with stable knockdown of PHLDA1 and performed functional studies. To achieve reduced PHLDA1 expression we used shRNA plasmid transfection and then changes in cell morphology and biological behavior were assessed. We found that PHLDA1 downregulation induced marked morphological alterations in MCF10A cells, such as changes in cell-to-cell adhesion pattern and cytoskeleton reorganization. Regarding cell behavior, MCF10A cells with reduced expression of PHLDA1 showed higher proliferative rate and migration ability in comparison with control cells. We also found that MCF10A cells with PHLDA1 knockdown acquired invasive properties, as evaluated by transwell Matrigel invasion assay and showed enhanced colony-forming ability and irregular growth in low attachment condition. Altogether, our results indicate that PHLDA1 downregulation in MCF10A cells leads to morphological changes and a more aggressive behavior.

Entities:  

Keywords:  MCF10A; PHLDA1; aggressive phenotype; breast cancer; invasion; mammary epithelial cells; migration

Mesh:

Substances:

Year:  2017        PMID: 28640659      PMCID: PMC5810790          DOI: 10.1080/19336918.2017.1313382

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN: 1933-6918            Impact factor:   3.405


  29 in total

1.  Characterization and isolation of stem cell-enriched human hair follicle bulge cells.

Authors:  Manabu Ohyama; Atsushi Terunuma; Christine L Tock; Michael F Radonovich; Cynthia A Pise-Masison; Steven B Hopping; John N Brady; Mark C Udey; Jonathan C Vogel
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

2.  A novel gene product that couples TCR signaling to Fas(CD95) expression in activation-induced cell death.

Authors:  C G Park; S Y Lee; G Kandala; S Y Lee; Y Choi
Journal:  Immunity       Date:  1996-06       Impact factor: 31.745

3.  PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer.

Authors:  Emmanuel O Johnson; Kuei-Hua Chang; Yolanda de Pablo; Soumitra Ghosh; Rutika Mehta; Sunil Badve; Kavita Shah
Journal:  J Cell Sci       Date:  2011-08-15       Impact factor: 5.285

4.  Ultrastructural and immunocytochemical characterization of an immortalized human breast epithelial cell line, MCF-10.

Authors:  L Tait; H D Soule; J Russo
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

5.  Established and Suspected Risk Factors in Breast Cancer Aetiology.

Authors:  Alexander Kluttig; Andrea Schmidt-Pokrzywniak
Journal:  Breast Care (Basel)       Date:  2009-04-24       Impact factor: 2.860

Review 6.  Phosphoinositides in Control of Membrane Dynamics.

Authors:  Kay O Schink; Kia-Wee Tan; Harald Stenmark
Journal:  Annu Rev Cell Dev Biol       Date:  2016-08-15       Impact factor: 13.827

Review 7.  Genetic susceptibility for breast cancer: how many more genes to be found?

Authors:  R A Oldenburg; H Meijers-Heijboer; C J Cornelisse; P Devilee
Journal:  Crit Rev Oncol Hematol       Date:  2007-05-10       Impact factor: 6.312

8.  Pleckstrin homology-like domain, family A, member 1 (PHLDA1) and cancer.

Authors:  Maria Aparecida Nagai
Journal:  Biomed Rep       Date:  2016-01-25

Review 9.  The complex genetic landscape of familial breast cancer.

Authors:  Lorenzo Melchor; Javier Benítez
Journal:  Hum Genet       Date:  2013-04-05       Impact factor: 4.132

10.  TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation.

Authors:  Michael D Oberst; Stacey J Beberman; Liu Zhao; Juan Juan Yin; Yvona Ward; Kathleen Kelly
Journal:  BMC Cancer       Date:  2008-07-02       Impact factor: 4.430

View more
  4 in total

1.  Whole-exome sequencing of familial esophageal squamous cell carcinoma identified rare pathogenic variants in new predisposition genes.

Authors:  F F Golyan; T E Druley; M R Abbaszadegan
Journal:  Clin Transl Oncol       Date:  2019-07-18       Impact factor: 3.405

2.  A Novel 8-Gene Prognostic Signature for Survival Prediction of Uveal Melanoma.

Authors:  Zhongjun Tang; Kebo Cai
Journal:  Anal Cell Pathol (Amst)       Date:  2021-08-14       Impact factor: 2.916

3.  PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer.

Authors:  Abbie E Fearon; Edward P Carter; Natasha S Clayton; Edmund H Wilkes; Ann-Marie Baker; Ekaterina Kapitonova; Bakhouche A Bakhouche; Yasmine Tanner; Jun Wang; Emanuela Gadaleta; Claude Chelala; Kate M Moore; John F Marshall; Juliette Chupin; Peter Schmid; J Louise Jones; Michelle Lockley; Pedro R Cutillas; Richard P Grose
Journal:  Cell Rep       Date:  2018-02-27       Impact factor: 9.423

4.  The expression patterns and prognostic significance of pleckstrin homology-like domain family A (PHLDA) in lung cancer and malignant mesothelioma.

Authors:  Camila M Baldavira; Juliana Machado-Rugolo; Tabatha G Prieto; Daniel R Bastos; Marcelo Balancin; Alexandre M Ab'Saber; Lygia B Yaegashi; Paola C Souza; Cecilia Farhat; Teresa Y Takagaki; Maria Ap Nagai; Vera L Capelozzi
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.